PARP inhibitor-based combinations in first-line metastatic castration-resistant prostate cancer: A meta-analysis
In brief
PARP inhibitor combinations cut prostate cancer progression risk by 34%
In three phase III trials involving 2,024 men with first-line metastatic castration-resistant prostate cancer, adding a PARP inhibitor to androgen-targeted therapy cut progression or death by 34% and mortality by 21%. Benefits were greatest in tumors with BRCA1/2 alterations, while anemia and other blood-related side effects increased; treatment choice depends on weighing these gains against added toxicity.
- Journal
- Urologic oncology (Q1)
- Published
- 10 November 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Wala Ben Kridis, Afef Khanfir
- PMID
- 43009426
- DOI
- 10.1016/j.urolonc.2026.10.013
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (paper of the day, 15 November 2026): Phase III meta-analysis improves PFS in mCRPC
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors combined with androgen receptor pathway inhibitors (ARPIs) have emerged as a promising therapeutic strategy for metastatic castration-resistant prostate cancer (mCRPC). We performed a systematic review and meta-analysis of phase III studies evaluating PARP inhibitor-ARPI combinations in the first-line mCRPC setting. PubMed/MEDLINE, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were systematically searched. Eligible studies were randomized phase III trials comparing a PARP inhibitor plus an ARPI with the corresponding ARPI-based control regimen in first-line mCRPC. The primary endpoint was progression-free survival (PFS), while overall survival (OS) was a key secondary endpoint. Three phase III trials (PROpel, MAGNITUDE, and TALAPRO-2) comprising 2,024 patients were included. PARP inhibitor-ARPI combinations significantly improved PFS compared with ARPI-based therapy alone (HR 0.66, 95% confidence interval [CI] 0.58-0.76; P < 0.001), corresponding to a 34% reduction in the risk of progression or death. A significant OS benefit was also observed (HR 0.79, 95% CI 0.70-0.89; P < 0.001), representing a 21% reduction in mortality risk. Heterogeneity was absent for both endpoints (I² = 0%). In patients with BRCA1/2 alterations, treatment effects were more pronounced, with pooled HRs of 0.40 (95% CI 0.31-0.53) for PFS and 0.55 (95% CI 0.42-0.71) for OS. Combination therapy was associated with increased hematologic toxicity, particularly anemia, but adverse events were generally manageable. PARP inhibitor-ARPI combinations significantly improve progression-free and OS in first-line mCRPC, with the greatest benefit observed in BRCA1/2-altered tumors.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.